Standout Papers

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02)... 2013 2026 2017 2021 398
  1. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial (2013)
    Hugo Ford, Andrea Marshall et al. The Lancet Oncology

Immediate Impact

25 by Nobel laureates 5 from Science/Nature 68 standout
Sub-graph 1 of 19

Citing Papers

Precision treatment in advanced hepatocellular carcinoma
2024 Standout
Hepatocellular carcinoma
2022 Standout

Works of Daniel Swinson being referenced

Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK audit
2021
Sorafenib for the Treatment of Advanced Hepatocellular Cancer – a UK Audit
2016

Author Peers

Author Last Decade Papers Cites
Daniel Swinson 758 353 547 44 1.4k
Kanwal Raghav 341 357 554 51 1.1k
Hisashi Usuki 441 438 430 70 1.0k
Lawrence Schwartz 498 262 438 37 1.6k
Y-J. Bang 549 272 714 54 1.3k
Angelica Petrillo 335 224 527 68 1.1k
Inkeun Park 849 441 649 98 1.7k
Syed A. Ahmad 535 680 778 58 1.6k
Olivier Dubreuil 488 368 907 54 1.6k
Antonia Strippoli 422 318 516 65 1.0k
R. Morant 484 184 705 54 1.3k

All Works

Loading papers...

Rankless by CCL
2026